{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:58:26Z","timestamp":1795125506556,"version":"4.10.3"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.euroneuro.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T22:45:49Z","timestamp":1682808349000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder"],"prefix":"10.1016","volume":"73","author":[{"given":"Mark","family":"Weiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-9101","authenticated-orcid":false,"given":"Igor","family":"Nastas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-930X","authenticated-orcid":false,"given":"Israel","family":"Dudkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.04.007_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacl.2020.10.007","article-title":"Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies","volume":"15","author":"Adhikari","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0002","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/schbul\/sbab040","article-title":"Misreporting of results of research in psychiatry","volume":"47","author":"Bowcut","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0003","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"\u00c7akici","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0004","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v62n1003","article-title":"The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials","author":"Davis","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0005","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/14737175.7.7.789","article-title":"Inflammation and schizophrenia","volume":"7","author":"Fan","year":"2007","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0006","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fpsyt.2020.00160","article-title":"The role of inflammation in the treatment of schizophrenia","author":"Fond","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0007","series-title":"EC-DEU Assessment Manual For Psychopharmacology, Revised CGI Clinical Global Impressions","first-page":"76","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0008","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2008.03.024","article-title":"Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)","volume":"102","author":"Keefe","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial [CME]","volume":"71","author":"Laan","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0012","first-page":"85","article-title":"The UKU (Udvalg for Kliniske Undersogelser) side effect rating scale","volume":"76","author":"Lingjaerd","year":"1987","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/eip.12859","article-title":"Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence, proposed mechanisms and implications for treatment","volume":"14","author":"Mongan","year":"2020","journal-title":"Early Interv Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0014","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00375","article-title":"COX-2 Inhibitors, Aspirin, and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders","volume":"10","author":"M\u00fcller","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0016","first-page":"S176","article-title":"Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease?","author":"M\u00fcller","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0017","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"M\u00fcller","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0018","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","article-title":"Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"39","author":"Nitta","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0019","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/1570159X16666180119144538","article-title":"Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review","volume":"16","author":"Orsolini","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0020","first-page":"S222","article-title":"Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia","author":"Rappard","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0021","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/00023210-200519100-00001","article-title":"COX-2 inhibitors as adjunctive therapy in schizophrenia","volume":"19","author":"Riedel","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10753-009-9178-3","article-title":"Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals","volume":"33","author":"Rosendo","year":"2010","journal-title":"Inflammation"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0023","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.psychres.2018.02.018","article-title":"Adjunctive therapy with statins in schizophrenia patients: a meta-analysis and implications","volume":"262","author":"Shen","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0025","doi-asserted-by":"crossref","unstructured":"Sommer, I.E., Begemann, M., Kahn, R., 2012. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.","DOI":"10.1016\/S0920-9964(12)70276-1"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0026","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/schbul\/sbab010","article-title":"Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial","volume":"47","author":"Sommer","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0027","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0028","first-page":"363","article-title":"Innate immune cells and C-reactive protein in acute first-episode psychosis and schizophrenia: relationship to psychopathology and treatment","volume":"46","author":"Steiner","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0029","series-title":"R: A language and Environment For Statistical Computing (Version 3.6. 1)","author":"Team","year":"2019"},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sbaa198","article-title":"Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: results of Two Randomized Controlled Trials","author":"Weiser","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.04.007_bib0032","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archneurol.2010.199","article-title":"3-Hydroxy-3-methylglutaryl\u2013Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases","volume":"67","author":"Willey","year":"2010","journal-title":"Arch. Neurol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:06:01Z","timestamp":1760378761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"alternative-id":["S0924977X23000718"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}